The Medicines Company First Quarter Financial Results and Conference Call Notice
PARSIPPANY, N.J.--(BUSINESS WIRE)--April 9, 2002--The Medicines Company (Nasdaq: MDCO - news) will be hosting a conference call beginning at 4:30 p.m. Eastern time April 23, 2002 to discuss its first quarter financial results. These results, for the quarter ended March 31, 2002, will be released at 4:00 p.m. Eastern time on April 23, 2002. Clive Meanwell, M.D., Ph.D., Executive Chairman, Dave Stack, President and Chief Executive Officer, and Peyton Marshall, Ph.D., Chief Financial Officer, will lead the conference call.
To listen to the conference call, please dial 800-472-8325 and request The Medicines Company 2002 First Quarter conference call. If you are calling from outside of the United States, please dial 1-706-679-0816. If you cannot attend the live call, a digital replay will be available through April 25. Please call 800-642-1687 in the U.S. or 1-706-645-9291 internationally and enter passcode 3798534. Additionally, this call is being webcast by CCBN and can be accessed at The Medicines Company's web site (www.themedicinescompany.com).
The Medicines Company was founded in 1996 to acquire, develop and commercialize selected pharmaceutical products in late stages of development and approved products. ANGIOMAX® (bivalirudin), the Company's lead product, is approved in the United States for use as an intravenous anticoagulant in combination with aspirin in patients with unstable angina undergoing coronary balloon angioplasty, and is expected to be the cornerstone product of a planned acute-care hospital franchise. The Company is also developing another intravenous agent, clevidipine, for the short-term control of high blood pressure in the hospital setting.
This press release contains forward-looking statements that involve a number of risks and uncertainties. For this purpose, any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the foregoing, the words, ``believes,'' ``anticipates,'' ``plans,'' ``expects,'' ``intends,'' and similar expressions are intended to identify forward-looking statements. Important factors that could cause actual results to differ materially from the expectations described in these forward-looking statements are set forth under the caption ``Factors that May Affect Future Results'' in the Company's Quarterly Report on Form 10-K filed with the Securities and Exchange Commission on April 1, 2002 and incorporated herein by reference. These risk factors include risks as to the commercial success of ANGIOMAX; how long the Company will be able to operate on its existing capital resources; whether the Company's products (other than ANGIOMAX for its approved indication) will advance in the clinical trials process, the timing of such clinical trials, whether the clinical trial results will warrant continued product development, whether and when, if at all, the Company's products will receive approval from the U.S. Food and Drug Administration or equivalent regulatory agencies, and for which indications, and, if such products receive approval, whether they will be successfully marketed; the Company's history of net losses; and the Company's dependence on third parties, including manufacturers, suppliers and collaborators. We do not assume any obligation to update any forward-looking statements.
--------------------------------------------------------------------------------
Contact:
The Medicines Company
Jill Sawdon, 617/225-9099 |
